- HCV infection is associated with a small but significant 2.5%-3.5% increase in absolute risk for cardiovascular disease (CVD) over a 10-year span.
Why this matters
- The role of HCV in CVD is controversial; some studies have reported increased risk, others none.
- Potential mechanisms include metabolic dysregulation as well as chronic inflammation and/or endothelial dysfunction.
- Analysis of participants aged 30-74 years with no CVD history in the US National Health and Nutrition Survey (NHANES 2007-2016; n=16,668) and Canadian Health Measures Survey (CHMS 2007-2015, n=10,115).
- HCV prevalence: NHANES, 1.95%; CHMS, 0.9%.
- Funding: Public Health Agency of Canada.
- HCV+ individuals had a distinct sociodemographic profile, but similar cardiometabolic risk factors, inflammatory markers, and micronutrient serum levels vs HCV-negative counterparts.
- NHANES showed higher mean Framingham Risk Score (FRS) values in HCV+ vs HCV-negative persons (15.3%±10.4% vs 12.1%±9.8%; P=.047).
- Mean 10-year FRS-estimated CVD risk was higher (“intermediate”) among HCV+ vs “low” among HCV-negative persons in:
- NHANES: 14.7±10.3 vs 10.0±10.0 (P<.001>
- CHMS: 10.5±8.8 vs 8.0±6.6 (P=.008).
- NHANES: 3.5% (P<.001>
- CHMS: 2.5% (P<.003>
- HIV status, drug use not captured.